Suppr超能文献

环氧化酶-2与结肠癌:化学预防的潜在靶点

COX-2 and colon cancer: potential targets for chemoprevention.

作者信息

Fournier D B, Gordon G B

机构信息

G.D. Searle & Co., Oncology and Chemoprevention, Skokie, Illinois 60077, USA.

出版信息

J Cell Biochem Suppl. 2000;34:97-102. doi: 10.1002/(sici)1097-4644(2000)77:34+<97::aid-jcb16>3.0.co;2-z.

Abstract

Evidence derived from several lines of investigation suggest that prostaglandins, metabolites of arachidonic acid, play an important role in colon cancer development. Elevated prostaglandin levels are found in colon cancers and their precursor lesions, adenomatous polyps. Agents such as aspirin and NSAIDs, which inhibit the generation of these arachidonic acid metabolites, are associated with a decreased risk of developing or dying from colon cancer. Both the amount of the agent used and the duration of exposure seem to be important variables. In animals, NSAIDs are among the most potent agents discovered for the reduction of tumors in both genetic and carcinogen-induced models. Data from human trials also suggests that NSAIDs such as sulindac can reduce the size and number of polyps in individuals with familial adenomatous polyposis (FAP). In parallel with the above findings, it is now understood that at least two forms of the enzyme responsible for the metabolism of arachidonic acid exist. One of these forms, COX-1, is generally considered a constitutive form that is responsible for maintaining normal physiologic function. Inhibition of COX-1 leads to many of the clinically undesirable side effects associated with NSAID use. The other known form of the enzyme, COX-2, is an inducible form that is found in increased levels in inflammatory states and in many cancers and their associated pre-malignant lesions. Levels of COX-2 are increased by exposure to mitogens and growth factors. Agents that specifically inhibit COX-2 are now in clinical development and appear to be well-tolerated and effective for the treatment of osteoarthritis and rheumatoid arthritis. The potential for use of COX-2 specific NSAIDs in the prevention of colon cancer is suggested from the distribution of COX-2 in adenomatous polyps and colon cancer and the effectiveness of these agents in genetic and carcinogen-induced animal models of colon cancer. The development of these agents for the prevention of colon cancer will be discussed.

摘要

来自多个研究领域的证据表明,前列腺素(花生四烯酸的代谢产物)在结肠癌发展过程中发挥着重要作用。在结肠癌及其癌前病变(腺瘤性息肉)中发现前列腺素水平升高。阿司匹林和非甾体抗炎药等能够抑制这些花生四烯酸代谢产物生成的药物,与降低患结肠癌或死于结肠癌的风险相关。所用药物的剂量和暴露时间似乎都是重要的变量。在动物中,非甾体抗炎药是在遗传和致癌物诱导模型中发现的最有效的肿瘤减少药物之一。人体试验数据也表明,舒林酸等非甾体抗炎药可以减少家族性腺瘤性息肉病(FAP)患者的息肉大小和数量。与上述发现同时,现在人们了解到至少存在两种负责花生四烯酸代谢的酶形式。其中一种形式,即COX - 1,通常被认为是一种组成型形式,负责维持正常生理功能。抑制COX - 1会导致许多与使用非甾体抗炎药相关的临床上不良的副作用。另一种已知的酶形式,即COX - 2,是一种诱导型形式,在炎症状态以及许多癌症及其相关的癌前病变中水平升高。暴露于有丝分裂原和生长因子会使COX - 2水平升高。专门抑制COX - 2的药物目前正在临床开发中,并且似乎对骨关节炎和类风湿关节炎的治疗耐受性良好且有效。从COX - 2在腺瘤性息肉和结肠癌中的分布以及这些药物在结肠癌的遗传和致癌物诱导动物模型中的有效性来看,使用COX - 2特异性非甾体抗炎药预防结肠癌具有潜力。将讨论这些药物用于预防结肠癌的开发情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验